ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 96

Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index and Skindex-29 with Cutaneous Childhood Lupus Erythematous

Pinar Ozge Avar Aydin1, Ashwaq AleEd2, Nora AlMutairi3, Sulaiman Al-Mayouf4, Hafize Emine Sonmez5, Seza Ozen6,7, Jennifer L. Huggins8 and Hermine Brunner9, 1Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Rheumatology, Department of Pediatrics, College of Medicine , Qassim University , Qassim , Saudi Arabia, Qassim, Saudi Arabia, 3Pedaitric Rheumatology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, 4Department of Pediatrics Rheumatology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, 5Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 6Department of Pediatric Rheumatology Hacettepe University Faculty of Medicine Ankara, Turkey, Ankara, Turkey, 7Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 8Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH, 9Rheumatology, PRCSG, Cincinnati, OH

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Cutaneous manifestations and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, May 18, 2017

Title: Clinical and Therapeutic Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose:

Characteristic inflammatory cutaneous lesions are common manifestations of children with systemic lupus erythematosus (cSLE); however they are among understudied areas of cSLE. The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) allows for measuring active inflammation and chronic damage and, it has been validated to determine the impact of therapy on the activity of the cutaneous manifestations in adults. The Skindex-29 is a skin-specific Quality of Life Score (QoL). Their validation in cSLE has not been shown.

Methods:

Patients with cSLE from different three centers were enrolled in a prospective longitudinal cohort study. Inclusion criteria were (1) being diagnosed with SLE according to the American College of Rheumatology criteria for SLE, (2) being diagnosed before 18th birthday, (3) being under 18 years of age at the enrollment, (4) having active or chronic mucocutaneous involvement of lupus. In this ongoing study; CLASI, the PedsQL Generic Core scale and the Rheumatology Module, the Skindex-29, physicians-rated cSLE activity (SLEDAI) and completed the SLICC/ACR damage index (SDI) were achieved besides the clinical and laboratory data obtained from two routine visits 6 months apart.

Results:

The study cohort consisted of 48 patients (90% females) with a mean age at the first visit 14.5 years (ranges: 3-18). 62.5 % of patients completed their second visits. Patients had moderately active cSLE (total SLEDAI scores: 8.7±7.3) and 40 % had a SDI score >0. The mean mucocutaneous domain (MC) scores were 2.2±1.7 for SLEDAI-MC and 0.1±0.1 for SDI-MC at their baseline visits.

The average scores of patients were 6.7±7.6 for SLEDAI, 1.6±1.7 for SLEDAI-MC and 0.1±0.1 for SLICC-MC; 53 % had a SDI score >0 at their second visits. We found that SLEDAI, SLEDAI-MC, SDI-MC, the Skindex, CLASI activity and damage scores are strongly correlated with each other (p<0.01). In addition, cSLE activity (SLEDAI, SLEDAI-MC), damage (SDI, SDI-MC) and QoL are moderately associated with CLASI and the Skindex scores.

Conclusion:

We conclude that CLASI and the Skindex demonstrate a high validity and reliability when used in cSLE showing mucocutaneous involvement.


Disclosure: P. O. Avar Aydin, None; A. AleEd, None; N. AlMutairi, None; S. Al-Mayouf, None; H. E. Sonmez, None; S. Ozen, None; J. L. Huggins, None; H. Brunner, None.

To cite this abstract in AMA style:

Avar Aydin PO, AleEd A, AlMutairi N, Al-Mayouf S, Sonmez HE, Ozen S, Huggins JL, Brunner H. Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index and Skindex-29 with Cutaneous Childhood Lupus Erythematous [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/correlation-and-responsiveness-of-cutaneous-lupus-disease-area-and-severity-index-and-skindex-29-with-cutaneous-childhood-lupus-erythematous/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-and-responsiveness-of-cutaneous-lupus-disease-area-and-severity-index-and-skindex-29-with-cutaneous-childhood-lupus-erythematous/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology